2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppressionExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomes
2014
Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate. JAMA Internal Medicine 2014, 174: 721-729. PMID: 24687044, PMCID: PMC4074594, DOI: 10.1001/jamainternmed.2014.601.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCD4 lymphocyte countViral suppressionHIV viral suppressionLymphocyte countObserved therapyRNA levelsBaseline HIV-1 RNA levelsMean HIV-1 RNA levelHuman immunodeficiency virus (HIV) treatmentHuman immunodeficiency virus managementHIV treatment outcomesRetrospective cohort studyAntiretroviral therapy regimensHIV-1 RNAPsychiatric disorder severityLogistic regression modelsCommunity-based resourcesDuration of incarcerationRace/ethnicityART regimenContinuous ARTPrescribed pharmacotherapyAntiretroviral therapyART regimens
2010
A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization
Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug And Alcohol Dependence 2010, 112: 178-193. PMID: 20705402, PMCID: PMC2997193, DOI: 10.1016/j.drugalcdep.2010.06.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHealth care utilizationHIV treatment outcomesAlcohol use disorderPoor HIV treatment outcomesCare utilizationTreatment outcomesAntiretroviral therapyUse disordersImpact of AUDHealth service utilizationHIV/AIDSCD4 countHIV statusMedication adherenceService utilizationDATA SYNTHESISAnimal studiesElectronic databasesSystematic reviewAlcohol useTherapyPrimary articlesGoogle ScholarAdherenceOutcomesDAART for Human Immunodeficiency Virus–Infected Patients: Studying Subjects Not at Risk for Nonadherence and Use of Untested Interventions
Altice FL, Springer SA. DAART for Human Immunodeficiency Virus–Infected Patients: Studying Subjects Not at Risk for Nonadherence and Use of Untested Interventions. JAMA Internal Medicine 2010, 170: 109-110. PMID: 20065210, PMCID: PMC2825565, DOI: 10.1001/archinternmed.2009.459.Peer-Reviewed Original ResearchMeSH KeywordsAdenineAdministration, OralAdolescentAdultAgedAnti-HIV AgentsDeoxycytidineDose-Response Relationship, DrugDrug Resistance, ViralEmtricitabineFemaleGenotypeHIV InfectionsHIV-1HumansLopinavirMaleMiddle AgedOrganophosphonatesPatient CompliancePyrimidinonesRandomized Controlled Trials as TopicRNA, ViralStavudineTenofovirTreatment OutcomeYoung Adult
2009
Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy
Springer SA, Chen S, Altice F. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care 2009, 21: 976-983. PMID: 20024753, PMCID: PMC2797133, DOI: 10.1080/09540120802657555.Peer-Reviewed Original ResearchConceptsInjection drug usersCES-D scoresMajor depressive disorderAntiretroviral therapyCD4 countDepressive symptomsDrug usersDrug useHIV-1 RNA levelsProspective clinical trialsSubstance abuse treatment servicesSelf-administered therapyActive drug useNon-Caucasian raceSix-month followSix-month dataAntidepressant medicationAntiretroviral treatmentPoor adherenceSymptomatic responseMale genderClinical trialsDepressive disorderDepression ScaleDrug treatmentPersistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial
Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of Virological Benefits Following Directly Administered Antiretroviral Therapy Among Drug Users: Results From a Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 50: 176-181. PMID: 19131891, PMCID: PMC2670996, DOI: 10.1097/qai.0b013e3181938e7e.Peer-Reviewed Original ResearchConceptsSelf-administered therapyHIV-1 RNACD4 lymphocyte countVirological successDrug usersAntiretroviral therapyLymphocyte countMonths postinterventionLog10 HIV-1 RNAProportion of subjectsActive drug usersVirological benefitVirological outcomesSecondary outcomesControlled TrialsPrimary outcomeBlood samplesDAARTMultivariate analysisBenefits persistTherapyTrialsAdditional strategiesOutcomesPostintervention
2007
Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy
Maru DS, Bruce RD, Walton M, Mezger JA, Springer SA, Shield D, Altice FL. Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy. AIDS And Behavior 2007, 12: 284-293. PMID: 18085432, PMCID: PMC2693908, DOI: 10.1007/s10461-007-9336-2.Peer-Reviewed Original ResearchConceptsSelf-administered therapyAntiretroviral therapyDrug usersComposite adherence scorePresence of depressionDrug treatment programsControlled TrialsSix-month periodAdherence scoreOwn medicationsHealth outcomesDAARTMajor causeTherapyAdherenceDiscontinuationHIVSuccessful program designTrialsParticipantsHospitalizationMedicationsLack of willingnessVisitsDirectly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance
Maru DS, Kozal MJ, Bruce RD, Springer SA, Altice FL. Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2007, 46: 555-563. PMID: 18193497, PMCID: PMC2684061, DOI: 10.1097/qai.0b013e318158c0bd.Peer-Reviewed Original ResearchConceptsDrug resistance mutationsNew drug resistance mutationsSelf-administered therapyDrug usersAntiretroviral therapyHIV genotypic resistance testingFuture drug optionsAntiretroviral drug resistanceGenotypic resistance testingGenotypic sensitivity scoreMain outcome measuresMedication resistanceModified intentionVirologic benefitAntiretroviral resistanceTreat analysisClinical outcomesDrug mutationsDrug optionsOutcome measuresAdjusted probabilityDrug resistanceResistance mutationsHIVEffective interventionsSuperiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of Directly Administered Antiretroviral Therapy over Self-Administered Therapy among HIV-Infected Drug Users: A Prospective, Randomized, Controlled Trial. Clinical Infectious Diseases 2007, 45: 770-778. PMID: 17712763, PMCID: PMC2693907, DOI: 10.1086/521166.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsSelf-administered therapyT-lymphocyte countsDrug usersAntiretroviral therapyLymphocyte countRNA levelsPrimary outcomeProportion of patientsGreater mean reductionHIV treatment programsLog10 copies/Human immunodeficiency virusCopies/mLDAART groupVirologic outcomesSecondary outcomesControlled TrialsImmunodeficiency virusPoor adherenceTreatment adherenceEntry criteriaTreat approachCopies/Mean changeAntiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners
Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyImmunological outcomesHIV-1 RNA levelsCells/mulActive antiretroviral therapyEffective antiretroviral therapyRetrospective cohort studyDuration of therapyKaplan-Meier curvesHIV-1 RNAProportion of subjectsHAART strategyTriple NRTICohort studyCopies/Incarceration periodsTreatment strategiesHigh prevalenceMean changeStudy groupNRTIsHIVTherapyRNA levelsLaboratory data
2004
Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication
Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a Directly Administered Antiretroviral Therapy Intervention for HIV-Infected Drug Users: Implications for Program Replication. Clinical Infectious Diseases 2004, 38: s376-s387. PMID: 15156426, DOI: 10.1086/421400.Peer-Reviewed Original ResearchConceptsMedian HIV-1 RNA loadDrug usersHIV-1 RNA loadMost subjectsHuman immunodeficiency virusSelf-administered therapySyringe exchange programsMedian CD4Antiretroviral therapyDaily regimensMedical comorbiditiesImmunodeficiency virusEmergency departmentRNA loadMethadone clinicsMedication administrationOwn medicationsCopies/Major depressionMedical appointmentsTherapy interventionCell countDAARTCells/Medical servicesEffectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community
Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of Antiretroviral Therapy among HIV-Infected Prisoners: Reincarceration and the Lack of Sustained Benefit after Release to the Community. Clinical Infectious Diseases 2004, 38: 1754-1760. PMID: 15227623, DOI: 10.1086/421392.Peer-Reviewed Original ResearchConceptsMean CD4 lymphocyte countCD4 lymphocyte countAntiretroviral therapyLymphocyte countCopies/Sustained benefitHuman immunodeficiency virus type 1 RNA levelsActive antiretroviral therapyRetrospective cohort studyLog10 copies/Mu LHAART useCohort studyHIV diseaseLymphocyte responsesPoor outcomeIncarcerated patientsRNA levelsLaboratory dataTherapyCorrectional settingsIncarceration periodsOutcomesPeriod of incarcerationCount
2003
Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users
Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH. Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. Journal Of Urban Health 2003, 80: 416-427. PMID: 12930880, PMCID: PMC3455979, DOI: 10.1093/jurban/jtg053.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusNondetectable viral loadCD4 lymphocyte countDrug treatmentDrug usersLymphocyte countViral loadHIV therapyBaseline HIV-1 RNA levelsNeedle exchangeHealth servicesHIV-1 RNA levelsPilot studyPotent antiretroviral combinationUtilization of HAARTActive antiretroviral therapyAntiretroviral therapy regimensHIV-1 RNACommunity-based health interventionsAdverse side effectsActive drug usersFormal drug treatmentImmunodeficiency syndrome (AIDS) incidenceSmall pilot studyActive heroin injectors